This is a working overview of regulatory status, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-27 and is reviewed periodically as new material appears.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
== Biosynthesis == At least two enzyme families convert L-amino acids to D-amino acids. Amino-acid racemase, a PLP-dependent enzyme, racemizes amino acids via the formation of the α-iminoacids, where the stereogenic center is lost. L-amino-acid oxidases convert L-amino acids to the α-ketoacids, which are susceptible to reductive amination. Some amino acids are prone to racemization, one example being lysine, which racemizes via formation of pipecolic acid. In peptides, L-amino acid residues slowly racemize, resulting in the formation of some D-amino acid residues. Racemization occurs via deprotonation of the methyne that is alpha to the amido group. Rates increase with pH. Many D-amino acids found in higher organisms are derived from microbial sources. The D-alanine in peptidoglycans that comprise bacterial cell walls helps its host resist attack by proteolytic enzymes. Several antibiotics, e.g. bacitracin, contain D-amino acid residues.
=== Determination of concentration using a calibration curve === Standard solutions are commonly used to determine the concentration of an analyte species via calibration curve. A calibration curve is obtained by measuring a series of standard solutions with known concentrations, which can be used to determine the concentration of an unknown sample using linear regression analysis. For example, by comparing the absorbance values of a solution with an unknown concentration to a series of standard solutions with varying concentrations, the concentration of the unknown can be determined using Beer's Law. Any form of spectroscopy can be used in this way so long as the analyte species has substantial absorbance in the spectra. The standard solution is a reference guide to discover the molarity of unknown species. The matrix effect can negatively affect the efficiency of a calibration curve due to interactions between matrix and the analyte response. The matrix effect can be reduced by the addition of internal standards to the standard solutions, or by using the standard addition method.
A common and popular fish for tropical freshwater aquaria, C. macracanthus is a visually pleasing species. Although specimens in the wild will reach 40 to 50 cm, in the aquaria it is uncommon for C. macracanthus to attain more than 15 to 20 cm fork length. They are a very long-lived species, living up to 30 years. These fish have bifurcated spines under the eyes. They are thought to be used as a defence mechanism and possibly, for obtaining prey. C. macracanthus will associate with other benthic species in the aquaria if kept singly or with few other specimens. They make suitable tank-mates for any non-aggressive community fishes, but do not thrive when kept with larger, more dominant species. Occasionally C. macracanthus will exhibit erratic swimming patterns, such as swimming on their sides or upside down. This is not usually a sign of illness, however, and the fish will typically resume normal behaviour almost instantly. As C. macracanthus is found in riverine environments it is able to cope with good flow rates of water in the aquaria. Aquascapes may replicate this environment to suit the requirements of the species with areas of high flow, but also typically include areas of low flow to allow the fish to rest. C. macracanthus is also fond of cover and is not overly accustomed to bright lighting. The fish will often seek areas of shade or cover in which to rest during the day and become more active when light levels are more subdued. The barbels of clown loaches are known to be easily damaged by rough substrates, such as gravel, in aquaria.
=== Death === Sunny remained in a persistent vegetative state until her death from cardiopulmonary arrest on December 6, 2008, at Mary Manning Walsh Nursing Home in New York City. Her memorial service, given by her three children, was held on January 14, 2009, at the Brick Presbyterian Church in New York, which was the same church where the von Bülows married.
Sources: en.wikipedia.org
Dynamic and interactive HTML5 charting Improved and revamped scheduler (additional features over what is added in CF10 Standard) Object relational mapping enhancements The lists above were obtained from the Adobe web site pages describing "new features", as listed first in the links in the following list. CF10 was originally referred to by the codename Zeus, after first being confirmed as coming by Adobe at Adobe MAX 2010, and during much of its prerelease period. It was also commonly referred to as "ColdFusion next" and "ColdFusion X" in blogs, on Twitter, etc., before Adobe finally confirmed it would be "ColdFusion 10". For much of 2010, ColdFusion Product Manager Adam Lehman toured the US setting up countless meetings with customers, developers, and user groups to formulate a master blueprint for the next feature set. In September 2010, he presented the plans to Adobe where they were given full support and approval by upper management. The first public beta of ColdFusion 10 was released via Adobe Labs on 17 February 2012.
=== Proteasomal deubiquitinases === Ubiquitin chains conjugated to a protein targeted for proteasomal degradation are normally removed by any one of the three proteasome-associated deubiquitylating enzymes (DUBs), which are Rpn11, Ubp6/USP14 and UCH37. Rpn11 is the essential DUB responsible for the en block removal of the ubiquitin signal from the substrate, while Ubp6/USP14 and UCH37 have been proposed to edit the ubiquitin code. Ubp6 knockouts in Saccharomyces cerevisiae are viable, and there is no homolog of UCH37 in budding yeast, though they exist in Schizosaccharomyces pombe and higher eukaryotes. This process recycles ubiquitin and is essential to maintain the ubiquitin reservoir in cells.
==== Canonical pathway ==== The canonical Wnt pathway (or Wnt/β-catenin pathway) is the Wnt pathway that causes an accumulation of β-catenin in the cytoplasm and its eventual translocation into the nucleus to act as a transcriptional coactivator of transcription factors that belong to the TCF/LEF family. Without Wnt, β-catenin would not accumulate in the cytoplasm since a destruction complex would normally degrade it. This destruction complex includes the following proteins: Axin, adenomatosis polyposis coli (APC), protein phosphatase 2A (PP2A), glycogen synthase kinase 3 (GSK3) and casein kinase 1α (CK1α). It degrades β-catenin by targeting it for ubiquitination, which subsequently sends it to the proteasome to be digested. However, as soon as Wnt binds Fz and LRP5/6, the destruction complex function becomes disrupted. This is due to Wnt causing the translocation of the negative Wnt regulator, Axin, and the destruction complex to the plasma membrane. Phosphorylation by other proteins in the destruction complex subsequently binds Axin to the cytoplasmic tail of LRP5/6. Axin becomes de-phosphorylated and its stability and levels decrease. Dsh then becomes activated via phosphorylation and its DIX and PDZ domains inhibit the GSK3 activity of the destruction complex. This allows β-catenin to accumulate and localize to the nucleus and subsequently induce a cellular response via gene transduction alongside the TCF/LEF (T-cell factor/lymphoid enhancing factor) transcription factors.
One of Proudhon's keenest students was the Russian revolutionary Mikhail Bakunin, who adopted his critiques of private property and government, as well as his views on the desirability of anarchy. During the Revolutions of 1848, Bakunin wrote of his hopes of igniting a revolutionary upheaval in the Russian Empire, writing to the German poet Georg Herwegh that "I do not fear anarchy, but desire it with all my heart". Although he still used the negative definition of anarchy as disorder, he nevertheless saw the need for "something different: passion and life and a new world, lawless and thereby free." Bakunin popularised "anarchy" as a term, using both its negative and positive definitions, in order to respectively describe the disorderly destruction of revolution and the construction of a new social order in the post-revolutionary society. Bakunin envisioned the creation of an "International Brotherhood", which could lead people through "the thick of popular anarchy" in a social revolution. Upon joining the IWA, in 1869, Bakunin drew up a programme for such a Brotherhood, in which he infused the word "anarchy" with a more positive connotation. He declared: "We do not fear anarchy, we invoke it. For we are convinced that anarchy, meaning the unrestricted manifestation of the liberated life of the people, must spring from liberty, equality, the new social order, and the force of the revolution itself against the reaction."
Many women believe that sagging (ptosis) is caused by the failure of the Cooper's ligaments to support the breast tissue. In fact, ptosis is partly determined by genetic factors, but a review found that the biggest factors are higher body mass index, larger breast size, significant weight loss, smoking, number of pregnancies, and age. Many women incorrectly believe that wearing a brassiere prevents their breasts from sagging later in life and that breasts cannot anatomically support themselves. But bra manufacturers have stated that because breasts are formed of fatty tissue and not muscle, bras only affect the shape of breasts while they are being worn. Pathologically heavy breasts may cause pain in the woman's upper thoracic area, but this may be due to a poorly-fitting bra. Numerous reports state that 80–85% of women are wearing the wrong bra size. In middle-aged women, breast ptosis is caused by a combination of factors. If the woman has had children, postpartum hormonal changes will cause the depleted milk glands to atrophy. Women who experience multiple pregnancies repeatedly stretch the skin envelope during engorgement while lactating. As a woman's breasts grow in size during repeated pregnancies, the Cooper's ligaments that maintain the position of the mammary glands against the chest are stretched and gradually lose strength. Breast tissue and suspensory ligaments may also be stretched if the woman is overweight or loses and gains weight.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.